Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ganciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.71 |
| ▸ | PNP known ✓ | P00491 | 7/20 | 0.68 |
| ▸ | EDNRA known ✓ | P25101 | 1/20 | 0.68 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.68 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | VCP | P55072 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
| ▸ | HBB | P68871 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL3033 | 0.99 | BLM (1.00) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL2160505 | 0.99 | BLM (1.00) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481442 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL11093368 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10899902 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10901635 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL25915 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL10481436 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL11121521 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA | |
| Ganciclovir SCHEMBL2433042 | 0.98 | BLM (0.98) | BLMMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021107005-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CYTOMEGALOVIRUS-RELATED DISEASES | 国立研究開発法人国立成育医療研究センター | 2021-06-03 | — | — | WO | claimed |
| CN-112661757-B | Method for synthesizing valganciclovir hydrochloride | 河北合佳医药科技集团股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-112661757-A | Method for synthesizing valganciclovir hydrochloride | 河北合佳医药科技集团股份有限公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-112159407-A | Preparation method of valganciclovir | 湖北益泰药业股份有限公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-102702260-A | Methods of reducing nephrotoxicity in subjects administered with nucleoside | CHIMERIX INC | 2012-10-03 | — | — | CN | disclosed |
| WO-2011018771-A2 | PROCESS FOR THE PREPARATION OF VALGANCICLOVIR HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2011-02-17 | — | — | WO | disclosed |
| CN-1403084-A | Ganciclovir injection and its production process | WUHAN HUALONG BIOLOG PHARMACEU (CN) | 2003-03-19 | — | — | CN | disclosed |
| EP-0885224-B1 | PROCESS FOR PREPARING GANCICLOVIR DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2002-12-18 | — | — | EP | disclosed |
| EP-0885224-A1 | PROCESS FOR PREPARING GANCICLOVIR DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997027197-A1 | PROCESS FOR PREPARING GANCICLOVIR DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-07-31 | — | — | WO | disclosed |